News

The collaboration comprised the development and commercialization of new products based on botulium toxin and potential for Q-Med to distribute Medy-Tox’s existing botulinum toxin type A product. The

The main objective of the partnership is for Cellumen to develop a panel of Cellular Systems Biology (CSB) assays, as well as biosensors of key protein:protein interactions, that

Under the agreement, Advinus and Ortho-McNeil-Janssen Pharmaceuticals (OMJPI) have agreed to develop drug candidates for various disease targets. Advinus will be responsible for drug discovery and early clinical

The data generated will be used to better understand the unique benefit/risk characteristics of this important group of antimicrobial drugs, thereby helping to adapt and optimize future clinical

Agility will become part of GE Healthcare’s global diagnostic imaging services business, a provider of solutions enabling healthcare providers to achieve performance results through a combination of consulting

Prior to joining Seattle Genetics, Dr Waller was with Sonus Pharmaceuticals, where she served as senior vice president of regulatory affairs/quality assurance and clinical research until its merger

The Phase I study is expected to yield important information about the safety and immunogenicity of VaxInnate’s hemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at

This multicenter, open-label Phase II single-arm study is enrolling women with persistent or recurrent advanced ovarian, fallopian tube, and primary peritoneal epithelial cancers following at least one platinum-containing

Enzon is developing Oncaspar-IV to enhance the pharmaceutical properties of the currently available product. Oncaspar-IV utilizes an efficient modern process for manufacturing of L-asparaginase, and an improved PEG